Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych MEQs / SAQsConsultation-liaison psychiatry

Psych MEQs / SAQs · Consultation-liaison psychiatry

HD depression, irritability, suicide risk, and VMAT2 interface (MEQ)

FRANZCP-style MEQ on HD neuropsychiatry, suicide, irritability algorithms, and VMAT2 cautions.

20 marks20 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 46-year-old woman with genetically confirmed Huntington disease (motor-manifest for 4 years) is referred to CL. She takes tetrabenazine 25 mg three times daily (recently increased) and no antidepressant. Her husband reports 6 months of short fuse, two episodes of throwing objects, tearfulness, early morning wakening, and statements that 'the children would be better without a cursed mother.' She denies feeling sad on direct enquiry but scores high on a depression scale; she sits for long periods unless prompted (possible apathy overlap). No fever; swallow is impaired but weight is stable. (i) Formulate the neuropsychiatric syndromes and key differentials including delirium and pure apathy. (ii) Outline suicide risk assessment and acute safety steps. (iii) Give a stepped management plan for depression and irritability including example drug starts/doses and non-drug measures, and address the tetrabenazine–mood interface. (iv) Disposition, genetics/family issues, and advance care planning points. (20 marks)

Model answer

Reveal model answer

(i) Formulation and differentials. Leading cluster: major depression (biological symptoms, death wishes/burden beliefs) plus irritability/aggression (object throwing, short fuse) in manifest HD, with possible apathy overlap (sits unless prompted). Temporal link to tetrabenazine uptitration raises VMAT2-related dysphoria contribution.[1][5][8] Differentials: delirium (less likely without acute medical markers but consider aspiration/infection); pure apathy without depression; primary personality disorder (inadequate alone); substance use; medication toxicity; psychosis if paranoia emerges.[3][8]

(ii) Suicide risk. HD confers elevated suicidal ideation and behaviours; assess ideation, plan, intent, means (medication stockpile, weapons), past attempts, hopelessness, genetic 'curse' narrative, protective factors, and carer safety.[2][6] Acute steps: means restriction, increase supervision, crisis plan, consider hospital if intent/plan/high lethality or unsafe home, involve husband with consent/best-interest principles per local law (do not invent section numbers).[2][6]

(iii) Management. Joint neurology: review tetrabenazine dose/indication — TETRA-HD supports antichorea benefit but depression is a key adverse effect; reduce/stop if chorea allows or switch strategy.[5][7] Depression: start SSRI (e.g. sertraline 25–50 mg oral daily, titrate; or citalopram 10 mg oral daily with QTc/age caution); monitor activation and suicidality on initiation; sleep and psychological support.[3][7] Irritability: non-drug structure, carer education; SSRI often first drug step; if severe aggression persists, low-dose atypical (e.g. olanzapine 2.5–5 mg oral nocte or quetiapine 25 mg oral nocte) per expert algorithms, watch sedation/falls/rigidity.[3][4] For pure apathy components: OT/activation, not endless antidepressant stacking alone.[1][3]

(iv) Disposition. Multidisciplinary HD clinic follow-up (neurology, psychiatry, SLT for swallow, social work); genetics/family support for children at risk (no casual minor testing); advance care planning while capacity intact; carer support/respite; clear escalation for suicide or violence.[3][6][8]

Common errors

Common errors: ignoring tetrabenazine–depression link; calling everything 'understandable HD demoralisation'; missing suicide questions; high-dose haloperidol; testing asymptomatic children casually; inventing Mental Health Act sections; treating apathy as melancholia only.[2][3][5]

Examiner notes

High-scoring scripts name REGISTRY-level burden, suicide epidemiology, irritability algorithm (SSRI ± SGA), TETRA-HD/VMAT2 mood caution, and multidisciplinary HD care.[1][2][4][5]

References

  1. [1]van Duijn E, Craufurd D, Hubers AA, et al. Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY) J Neurol Neurosurg Psychiatry, 2014.PMID 24828898
  2. [2]Hubers AA, van Duijn E, Roos RA, et al. Suicidal ideation in a European Huntington's disease population J Affect Disord, 2013.PMID 23876196
  3. [3]Anderson KE, van Duijn E, Craufurd D, et al. Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders J Huntingtons Dis, 2018.PMID 30040737
  4. [4]Groves M, van Duijn E, Anderson K, et al. An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease PLoS Curr, 2011.PMID 21975525
  5. [5]Huntington Study Group Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial Neurology, 2006.PMID 16476934
  6. [6]van Duijn E, Fernandes AR, Abreu D, et al. Incidence of completed suicide and suicide attempts in a global prospective study of Huntington's disease BMJ Ment Health, 2021.PMID 34462049
  7. [7]van Duijn E Medical treatment of behavioral manifestations of Huntington disease Handb Clin Neurol, 2017.PMID 28947111
  8. [8]Rosenblatt A Neuropsychiatry of Huntington's disease Dialogues Clin Neurosci, 2007.PMID 17726917